PLRX - Pliant: Major Catalyst Expected Beginning Of 2023
- Results from the phase 2a INTEGRIS-PSC study using PLN-74809 for the treatment of patients with primary sclerosing cholangitis are expected 1st half of 2023.
- PLN-74809 is also being explored for the treatment of patients with idiopathic pulmonary fibrosis; Preliminary safety and efficacy data was released in 5 poster presentations at medical conference.
- The global idiopathic pulmonary fibrosis market is expected to reach $4.7 billion by 2027.
- Other indications in the pipeline include NASH fibrosis, Oncology targets and muscular dystrophy as well which de-risk the pipeline.
For further details see:
Pliant: Major Catalyst Expected Beginning Of 2023